Scientific literature

The table below lists 29 publications that have reported genetic associations for Levodopa-induced dyskinesia in Parkinson's disease. You can sort the table according to a certain column by clicking on the column name. You can also download the data. If you think that we missed a publication, please help us to further improve this resource by contacting us.

ReferenceTitlePubmed IDNote
Bialecka et al. 2004 Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. 15355491 Gene/variant curated
Cheshire al. 2014 Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. 24008922 Gene/variant curated
Contin et al. 2005 Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. 15747357 No gene/variant curated
de Lau et al. 2011 Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. 22083803 Gene/variant curated
Dos Santos et al. 2018 The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease. 30353564 Gene/variant curated
Foltynie et al. 2009 BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. 18977816 Gene/variant curated
Greenbaum et al. 2013 Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study. 23666822 No gene/variant curated
Hao et al. 2014 Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population. 25034874 Gene/variant curated
Healy et al. 2008 Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. 18539534 Gene/variant curated
Ivanova et al. 2012 NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. 22832729 No gene/variant curated
Kaiser et al. 2003 L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. 12796525 Gene/variant curated
Kaplan et al. 2014 Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease. 24633632 Gene/variant curated
König et al. Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease submitted Meta-analysis results
Kusters et al. 2018 Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. 29191473 Gene/variant curated
Lee et al. 2011 Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. 20945430 Gene/variant curated
Lesage et al. 2008 Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? 18981379 Gene/variant curated
Lin et al. 2007 Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. 17196621 No gene/variant curated
Martín-Flores et al. 2019 MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients. 29992529 Gene/variant curated
Molchadski et al. 2011 The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. 21108621 No gene/variant curated
Oliveri et al. 1999 Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. 10534246 Gene/variant curated
Paus et al. 2009 Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. 19353703 No gene/variant curated
Purcaro et al. 2019 DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease. 30316985 Gene/variant curated
Rieck et al. 2012 DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. 23171335 Gene/variant curated
Rieck et al. 2015 Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients? 25872644 Gene/variant curated
Rivera-Calimlim et al. 1984 Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. 6734032 No gene/variant curated
Schumacher-Schuh et al. 2014 Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. 24126708 Gene/variant curated
Strong et al. 2006 Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. 16435402 Gene/variant curated
Torkaman-Boutorabi et al. 2012 The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. 23093014 No gene/variant curated
Watanabe et al. 2003 Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. 14673217 No gene/variant curated
Yahalom et al. 2012 Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. 22703868 No gene/variant curated
Zappia et al. 2005 Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. 15824260 Gene/variant curated